Congressional Medicare advisers are weighing whether to recommend converting the 6% add-on to Part B drug reimbursement to a fixed fee capped at $175 for drugs that cost $15,000 or more, phased in starting with drugs costing above $700.
Medicare Payment Advisory Commission (MedPAC) staff members briefed commissioners during MedPAC’s Sept. 2 meeting about their analysis of the proposed Part B add-on payment change and other ways that Medicare could address the high prices of drugs covered under Part B.
Congressional Medicare advisers are weighing whether to recommend converting the 6% add-on to Part B drug reimbursement to a fixed fee capped at $175 for drugs that cost $15,000 or more, phased in starting with drugs costing above $700.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
